• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis
Publication date: Available online 3 September 2016 Source:The Lancet Diabetes & Endocrinology Author(s): Natriuretic Peptides Studies Collaboration Background Guidelines for primary prevention of cardiovascular diseases focus on prediction of coronary heart disease and stroke. We assessed whether or not measurement of N-terminal-pro-B-type natriuretic peptide (NT-proBNP) concentration could enable a more integrated approach than at present by predicting heart failure and enhancing coronary heart disease and stroke risk assessment. Methods In this individual-participant-data meta-analysis, we generated and harmoni...
Source: The Lancet Diabetes and Endocrinology - September 2, 2016 Category: Endocrinology Source Type: research

Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis
Publication date: Available online 26 February 2015 Source:The Lancet Diabetes & Endocrinology Background To investigate potential cardiovascular and other effects of long-term pharmacological interleukin 1 (IL-1) inhibition, we studied genetic variants that produce inhibition of IL-1, a master regulator of inflammation. Methods We created a genetic score combining the effects of alleles of two common variants (rs6743376 and rs1542176) that are located upstream of IL1RN, the gene encoding the IL-1 receptor antagonist (IL-1Ra; an endogenous inhibitor of both IL-1α and IL-1β); both alleles increase soluble IL-1Ra ...
Source: The Lancet Diabetes and Endocrinology - February 26, 2015 Category: Endocrinology Source Type: research

Assessing the cost‐effectiveness of Type 1 diabetes interventions: the Sheffield Type 1 Diabetes Policy Model
ConclusionsThe model is highly flexible and has broad potential application to evaluate the Dose Adjustment for Normal Eating research programme, other structured diabetes education programmes and other interventions for Type 1 diabetes.This article is protected by copyright. All rights reserved.
Source: Diabetic Medicine - December 3, 2013 Category: Endocrinology Authors: P. Thokala, J. Kruger, A. Brennan, H. Basarir, A. Duenas, A. Pandor, M. Gillett, J. Elliott, S. Heller Tags: Research Article Source Type: research

Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people
This study is registered at ClinicalTrials.gov (NCT01804439). Findings Our cohort consisted of 1 921 260 individuals, of whom 1 887 062 (98·2%) did not have diabetes and 34 198 (1·8%) had type 2 diabetes. We observed 113 638 first presentations of cardiovascular disease during a median follow-up of 5·5 years (IQR 2·1–10·1). Of people with type 2 diabetes, 6137 (17·9%) had a first cardiovascular presentation, the most common of which were peripheral arterial disease (reported in 992 [16·2%] of 6137 patients) and heart failure (866 [14·1%] of 6137 patients). Type 2 diabetes was positively associated wi...
Source: The Lancet Diabetes and Endocrinology - December 5, 2014 Category: Endocrinology Source Type: research

Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies
Publication date: Available online 11 April 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Bryan Williams, Thomas M MacDonald, Steve V Morant, David J Webb, Peter Sever, Gordon T McInnes, Ian Ford, J Kennedy Cruickshank, Mark J Caulfield, Sandosh Padmanabhan, Isla S Mackenzie, Jackie Salsbury, Morris J Brown Background In the PATHWAY-2 study of resistant hypertension, spironolactone reduced blood pressure substantially more than conventional antihypertensive drugs. We did three substudies to assess the mechanisms underlying this superiority and the pathogenesis of resistant hypertension. Methods PATHWA...
Source: The Lancet Diabetes and Endocrinology - April 12, 2018 Category: Endocrinology Source Type: research

Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial
In this report, we did a post-hoc analysis of cardiovascular and renal outcomes over 10 years following randomisation, including a 5 years post-intervention follow-up. As in the original trial, the primary endpoint was a composite of first cardiovascular event, including cardiovascular mortality, cardiovascular morbidity (non-fatal myocardial infarction and non-fatal stroke), revascularisation, and non-traumatic amputation, up to Dec 31, 2014. Analyses were based on the intention-to-treat principle. ADDITION-Europe is registered with ClinicalTrials.gov, NCT00237549.Findings343 general practices were randomly assigned to ro...
Source: The Lancet Diabetes and Endocrinology - November 21, 2019 Category: Endocrinology Source Type: research